Press Releases
About Us
Executive Management
Board of Directors
Palatin Scientific Advisors
Careers at Palatin
Corporate Governance
Reporting Hotline
Vyleesi
Research Focus
Clinical Pipeline
Our Focus: Peptide Drugs
Ocular Indications
PL8177 for Inflammatory Bowel Disease
PL8177 for COVID-19
Obesity and Diabetes
Cardiovascular Diseases
Licensing & Collaboration
Investors
Overview
Press Releases
Event Calendar
Webcasts
SEC Filings
Analyst Coverage
Investor Resources
Resources
Corporate Presentation
Vyleesi® (bremelanotide) for Hypoactive Sexual Desire Disorder (HSDD)
Poster Presentations
Scientific Publications
Patent Portfolio
Helpful Links
Contact Us
Contacting Palatin
Resources
Corporate Presentation
Palatin Technologies Corporate Presentation
March 2021